Other languages Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Delayed Nasdaq Other stock markets 01:30:00 2024-07-03 pm EDT			5-day change	1st Jan Change
0.2401 ^USD	+2.61%		+0.63%	-58.24%

Jun. 20	Maxim Initiates Virios Therapeutics at Buy Rating With $1 Price Target	MT
May. 20	Top Midday Decliners	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Top Midday Decliners	May. 20
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of NVIDIA Earnings due Wednesday	May. 20
Virios Therapeutics Prices $1.7 Million Common Stock Offering	May. 20
Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	Jan. 22
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	Jan. 02
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Virios Therapeutics, Inc. Announces Termination of At-The-Market Sales Agreement	23-09-18
Virios Therapeutics Shares Slump After Company Reports Q2 Loss	23-08-10
Virios Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Virios Therapeutics, Inc. Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as A New Treatment Option for Fibromyalgia	23-08-09
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-Covid Symptoms Following Treatment with A Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study	23-07-17
Virios Therapeutics Regains Compliance With Nasdaq Listing Rule	23-05-26
Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Virios Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14
Virios Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14
Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023	23-02-13
Better-Than-Expected Inflation Data Seen Boosting US Equities	22-12-13
US Stock Futures Move Higher Ahead of November Inflation Data	22-12-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Other languages

Filters